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The brain serotonergic system has an essential role in the physiological functions of the central
nervous system and dysregulation of serotonin (5-HT) homeostasis has been implicated in many
neuropsychiatric disorders. The tryptophan hydroxylase-2 (TPH2)g e n ei st h er a t e - l i m i t i n ge n z y m e
in brain 5-HT synthesis, and thus is an ideal candidate gene for understanding the role of
dysregulation of brain serotonergic homeostasis. Here, we characterized a common, but functional
single-nucleotide polymorphism (SNP rs1386493) in the TPH2 gene, which decreases efficiency
of normal RNA splicing, resulting in a truncated TPH2 protein (TPH2-TR) by alternative splicing.
TPH2-TR, which lacks TPH2 enzyme activity, dominant-negatively affects full-length TPH2 function,
causing reduced 5-HT production. The predicted mRNA for TPH2-TR is present in postmortem
brain of rs1386493 carriers. The rs13864923 variant does not appear to be overrepresented in
either global or multiplex depression cohorts. However, in combination with other gene variants
linked to 5-HT homeostasis, this variant may exhibit important epistatic influences.
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Introduction
Dysregulation of the brain serotonergic (5-HT) system
has been implicated in disorders such as major
depression,
1 attention-deficit/hyperactivity disorder,
2
schizophrenia,
3 aggression and suicidal behavior.
4
Among the genes involved in the brain 5-HT system,
the 5-HT transporter, especially its functional poly-
morphism in the promoter region, has been well
characterized for its association with anxiety and
depression.
5,6 Tryptophan hydroxylase-1 (TPH1) gene
was long considered the only rate-limiting enzyme in
5-HT synthesis, and its potential association with
various neuropsychiatric disorders has been widely
explored, but not without controversies.
4 However, a
second gene (TPH2) has been recently discovered as a
neuronal-specific gene
7 that controls brain 5-HT
synthesis,
8 whereas the previously known TPH1 gene
is essential for peripheral 5-HT synthesis.
7 Since its
discovery in 2003,
7 the TPH2 gene has been exten-
sively studied for its association with various neu-
ropsychiatric disorders, yielding over 500 genetic
variants in human. Except for a few examples of
functional characterization,
9–12 the majority of human
TPH2 genetic variants that have been found in the
introns, untranslated regions and promoter regions,
remain to be physiologically characterized.
13
In this study, we developed a functional approach
to characterize an intronic single-nucleotide poly-
morphism (SNP rs1386493) that was previously
identified in cohorts of neuropsychiatric disorders
and controls.
14,15 We used a minigene construct
carrying a partial TPH2 genomic DNA sequence to
address the physiological consequence of this SNP.
Our data indicate that SNP (rs1386493) reduces
normal splicing of intron 5 by generating an alter-
natively spliced transcript Q8N1X9 that can be
detected in postmortem brainstem tissues. The trun-
cated protein of Q8N1X9 is devoid of TPH2 enzyme
activity, and exerts a dominant-negative effect in vitro
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www.nature.com/mpon the ability of the normal Tph2 enzyme to support
5-HT synthesis. Although the allele frequency of this
SNP is not significantly different in cohorts we have
analyzed so far, our data provide a novel mechanism
that could regulate brain 5-HT synthesis and suggest
that genetic variations in the TPH2 gene could
contribute to the etiology of conditions associated
with dysfunction of the 5-HT system. Moreover,
homozygous carriers of this SNP were identified in
a subset of multiplex Caucasian families from the
NIMH Depression Pedigree. Therefore, our data suggest
that mutations in the TPH2 gene could be one of the
many contributing risk factors for major depression.
Materials and methods
IRB approval
The use of human genomic DNA samples and human
brainstem tissues was approved by Duke University
Medical Center Institutional Review Board. Brain samples
from human dorsal raphe were obtained at autopsy at
the Coroner’s Office of Cuyahoga County, Cleveland,
OH, USA. The study was performed using a protocol
approved by the Institutional Review Boards of University
Hospitals of Cleveland and the University of Mississippi
Medical Center. Informed consent was obtained from
the legally determined next-of-kin for all subjects.
Genotyping for SNP (rs1386493) by restriction fragment
length polymorphism
Genomic DNA (10ng) was amplified by PCR using
forward primer (50-TACCTTGTACTGATGTGTATTGG
TCAAGAGT) and reverse primer (50-TTGCACACATG
AATTTTCGTAAATGAGTCTA) to obtain an 889bp
fragment. The PCR fragment was digested with restric-
tion enzyme, Ava II (NEB, Ipswich, MA, USA), which
cut G-allele (GGACC) into two fragments of 605 and
284bp. A-allele (AGACC) containing fragment was not
cut by Ava II.
PCR amplification
Human TPH2 genomic DNA from bacterial artificial
chromosome clone RP11-89M22 (BACPAC Resource
Center, Oakland, CA, USA) was amplified using EXL
DNA polymerase (Stratagene, La Jolla, CA, USA). Taq
DNA polymerase (Fisher, Pittsburgh, PA, USA) was used
for genotyping and PCR amplification following RT–PCR.
The nested PCR was conducted by 20 cycles of ampli-
fication using the first set of primers, followed by
40 cycles of amplification using the second set of primers
and a diluted PCR solution from the first PCR as template.
RT–PCR and real-time RT–PCR analyses
Total RNA from PC12 cells stably transfected with
minigene constructs and human brainstem tissues was
prepared using TRI Reagent RNA Isolation Reagent
(Sigma, St Louis, MO, USA). Total RNA was then
treated with DNase I (Sigma). ProtoScript First Strand
cDNA Synthesis Kit (NEB) was then used to obtain
cDNA from total RNA or an Intron 5 specific sequence
(50-TTTTTTCTAATTTTCTCAATTCAGTTTT) was used
for detecting alternative splicing transcript in PC12 cells
(Figures 2c and e). Real-time RT–PCR was performed
using Platinum
s SYBR
s Green qPCR SuperMix-UDG
(Invitrogen, Carlsbad, CA, USA) with the following
conditions: denaturated at 951C for 3min followed by
40 cycles of amplification at 951Cf o r2s ,6 01C for 20s
and 721C for 30s. Gene expression was normalized to
neomycin-resistance gene (Neo
R).
PC12 cell lines and 5-HT detection
PC12 cell lines were maintained in DMEM media with
5% iron-supplemented bovine calf serum (HyClone,
Logan, UT, USA) and 5% equine serum (HyClone),
and 10% CO2. PC12 cells were transfected by electro-
poration (Bio-Rad, Hercules, CA, USA) as previously
described.
8,9 The production of 5-HTwas analyzed by
HPLC using an electrochemical detector as described
previously for the characterization of loss-of-function
TPH2 mutants in mice and human.
8,9 Western blotting
was performed using anti-hemagglutinin (Covance,
Princeton, NJ, USA) and anti-actin (Millipore, Billerica,
MA, USA) monoclonal antibodies and goat anti-mouse
secondary antibody conjugated with horseradish per-
oxidase (Pierce, Rockford, IL, USA).
Primer information
P1 (50-AGTGTGCTGGAATTCGAGCTCACTCTCTT),
P2 (50-TAAGCTTAGGCTCTTGGCGTTCGGAGGAT),
P3 (50-ACCAGGGATTTAAGGACAATGTCTATCGA
CAGAG),
P4 (50-ACTCTCGGCAAGCATGAGTGGGATAG),
P5 (50-AGTCATCTGACATACGTGGCTTGACG),
P6 (50-TGCTGGAATTCGAGCTCACTCTCTTC),
P7 (50-GCACGCTCAACATACACAAGGAGC),
P8 (50-ATGCAGCCAGCAATGATGATGTTTTCCAG),
P9 (50-AGCAGTGCCCGAAGAGCATCAGC),
P10 (50-TTGCACACATGAATTTTCGTAAATGAGTCTA).
RT–PCR for NeoR:
622bp-F (50-ATCAGAGCAGCCGATTGTCTGTTGT),
622bp-R (50-TACCCGTGATATTGCTGAAGAGCTT).
Real-time RT–PCR for NeoR:
qPCR-F (50-TCCTGTCATCTCACCTTGCTCCTGC),
qPCR-R (50-TGCTCTTCGTCCAGATCATCCTGATCG
AC).
RT–PCR for GAPDH:
Forward (50-TGC[A/C]TCCTGCACCACCAACT),
Reverse (50-[C/T]GCCTGCTTCACCACCTTC).
URLs
Ensembl: http://www.ensembl.org/index.html, National
Center for Biotechnology Information (NCBI) database:
http://www.ncbi.nlm.nih.gov, ESEfinder: http://rulai.
cshl.edu/tools/ESE/.
Results
Truncated TPH2 gene
The full-length human TPH2 gene (Ensembl:
ENST00000333850) possesses 11 exons and spans
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of TPH2 gene spanning only six exons has been
previously identified from a human brain cDNA
library and deposited as Q8N1X9 (Ensembl:
ENST00000266669).
16 By sequence comparison, we
identified that the first five exons of Q8N1X9 were
identical to those in TPH2, whereas its sixth exon
(exon a6A) was within the 22863bp-long intron 5 of
full-length TPH2 gene, and was 11897bp down-
stream of exon 5, suggesting Q8N1X9 represents an
alternatively spliced form of the TPH2 gene (Figure 1a).
Minigene constructs using partial TPH2 genomic DNA
As constitutive splicing of primary transcript RNA
requires both cis- and trans-acting factors,
17 the
existence of Q8N1X9 suggested that mutation(s) in
intron 5 and surrounding exon a6A junction might
give rise to conditions that compromised the normal
splicing of intron 5 leading to abnormal exon 5 and
exon a6A recognition. We searched known SNPs in
the NCBI database and located two candidate SNPs:
rs1386493 (G/A SNP) that was 154bp upstream of
exon a6A and rs10506644 (A/G SNP) that was within
exon a6A. To determine whether these two candidate
SNPs were functional by causing alternative splicing,
we used a previously established minigene construct
strategy consisting of constitutively active adeno-
virus exons and introns for splicing and neomycin-
resistance gene (Neo
R) for antibiotic selection.
18 As
the TPH2 gene possesses a 22863bp-long intron 5,
and most of the cis-acting elements for splicing are
usually in proximity of exons,
17 we chose to use
partial genomic DNA with B1000bp each upstream
and downstream of the exons of interest. We thus
amplified B2000bp of TPH2 genomic DNA sequen-
ces flanking exon 5 and exon 6, respectively, and
then cloned these DNA sequences into the minigene
construct to generate a vector construct (Figure 1b),
which allowed normal splicing for a transcript
containing adenovirus exons, exon 5 and exon 6
(Figures 2b and d). We then cloned a 3150-bp TPH2
genomic DNA sequence in intron 5 flanking the
alternatively spliced exon a6A into the vector con-
struct (wild-type, WT construct). We subsequently
generated mutant constructs at these two particular
positions: 6493A construct (G-to-A substitution cor-
responding to rs1386493) and 6644G construct (A-to-G
substitution corresponding to rs10506644)( F i g u r e1 b ) .
Figure 1 TPH2 genomic DNA and minigene constructs. (a) Full-length TPH2 genomic DNA sequence and its truncated
form, Q8N1X9 are shown with open boxes as exons. The red box highlights the alternatively spliced exon a6A in Q8N1X9.
(b) Partial TPH2 genomic DNA in minigene constructs. The constitutively active minigene construct consisted of adenovirus
exonic sequences (dark boxes adA and adD) and adenovirus intronic sequences (gray boxes B and C).
18 The vector construct
containing TPH2 genomic DNA with exon 5 (Ex5), exon 6 (Ex6) and their respective upstream and downstream intronic
sequences (blue and green) is referred to as vector construct. WT construct was generated when TPH2 genomic DNA
sequence in intron 5 (red), flanking the alternatively spliced exon a6A, was cloned into vector construct between 50- and 30-
intron 5 sequences as shown. Constructs into which G-to-A single-nucleotide polymorphism (SNP) (rs1386493) and A-to-G
(SNP rs10506644) substitutions were introduced are designated as 6493A and 6644G constructs, respectively. Dotted lines
indicate splicing patterns. Sizes of genomic DNA are illustrated and shown with arrows.
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splicing efficiency through alternative splicing
We transfected plasmids encoding vector alone, WT,
6493A, 6644G constructs into PC12 cells and gener-
ated stable cell lines expressing TPH2 minigene
constructs. RT–PCR was then performed using a
622-bp fragment of Neo
R as internal control (Figure
2a). The normal splicing was detected by PCR using
primer set (P1–P2) specific for the adenovirus exonic
sequences (Figure 2b). The vector construct produced
a single, 397bp PCR product (Figure 2b), which was
confirmed by sequence analysis as the normal spli-
cing product (Figure 2d, data not shown). When PC12
cells expressing the minigene constructs encoding
WT and mutants (6493A and 6644G) were analyzed,
the same single PCR product was shown. However,
the normal transcript of 397bp was reduced when
6493A construct was present (Figure 2b). To deter-
mine whether this decrease of normal exon 5–exon 6
transcripts in PC12 cells expressing 6493A was
significant, we performed real-time RT–PCR using
primer set (P3–P4; Figure 2d) and normalized to Neo
R
level. As shown in Figure 2f, an B40% decrease in
level of exon 5–exon 6 transcript was detected when
6493A construct was expressed, whereas level of
exon 5–exon 6 transcript was not affected in the
presence of 6644G construct as compared with the
WT construct. Thus, the decrease of normal splicing
efficiency suggested the existence of an alternative
spliced transcript. To address this possibility, we first
performed RT–PCR using a specific primer located
downstream of exon a6A, and carried out nested PCR
amplification to identify a 222-bp PCR fragment
(Figure 2e) corresponding to the formation of exon
5–exon a6A transcript in PC12 cells expressing 6493A
construct (Figure 2c). Therefore, we conclude that
SNP (rs1386493) induces an alternatively spliced
TPH2 transcript Q8N1X9, and decreases normal
intron 5 splicing efficiency.
TPH2-TR is a dominant-negative mutant
As Q8N1X9 was isolated from a cDNA library,
16 a3 0-
untranslated region sequence should be present
downstream of exon a6A, which is required for
mRNA stability.
19 To test this, we designed a green
fluorescent protein (GFP) construct under the CMV
promoter in the backbone of a pBluescript vector
(pBS-GFP; Figure 3a). In the absence of a downstream
30-untranslated region, pBS-GFP was unable to ex-
press GFP protein (Figure 3b). In contrast, when the
1500-bp downstream sequence of exon a6A (a6A/U)
was cloned to generate pBS-GFP-a6A/U, GFP expres-
sion was abundantly detected by western blotting
(Figure 3b), indicating a6A/U was sufficient to
stabilize Q8N1X9 mRNA. We next amplified exon
a6A and generated full-length cDNA of Q8N1X9
(TPH2-TR; Figure 4b), with an N-terminal hemagglu-
tinin epitope tag, and co-transfected it alone or along
with hemagglutinin-tagged full-length TPH2 into
PC12 cells and determined TPH2 activity by measur-
ing 5-HT production.
8,9 Western blotting indicated
that TPH2-TR was co-expressed with TPH2 (Figure
3c). Whereas TPH2-TR alone in PC12 cells was
devoid of enzyme activity, co-expressing full-length
TPH2 and increasing amounts of TPH2-TR, indicated
that despite being expressed at lower levels, TPH2-TR
exerted a dominant-negative effect on TPH2 for 5-HT
production (Figure 3d).
Figure 2 Assessment of the influence of intronic single-nucleotide polymorphisms (SNPs) on TPH2 splicing. (a–c) RT–PCR
detected a 397-bp normal spliced transcript (b, d) and a 622-bp Neo
R transcript (a) as an internal control. Nested PCR using
primer set (P1–P5) followed by (P6–P7) revealed a 222-bp transcript (c) as predicted by alternative splicing of exon a6A
(e). All PCR products were confirmed by sequence analysis (data not shown). (f) Real-time RT–PCR to measure normal
splicing of intron 6 using primer set (P3–P4) and Neo
R as an internal control indicated a significant decrease in the efficiency
of normal splicing only when SNP (rs1386493) was expressed. (All data are presented as means±s.d. Statistical significance
of all data presented was analyzed by Student’s t-test; N=10.)
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In order to confirm Q8N1X9 mRNA in human,
postmortem brainstem tissues were obtained from
the brain collection at the University of Mississippi
Medical Center. We first developed a restriction
fragment length polymorphism analysis for SNP
(rs1386493), and genotyped 143 genomic DNA sam-
ples (A-allele frequency 0.19) from the brain collec-
tion and obtained available brainstem tissue (pons/
medulla) of one wild-type (6493GG), one heterozy-
gous (6493GA) and two homozygous samples
(6493AA). We performed RT–PCR using nested PCR
amplification with primer set (P8–P5) followed by
primer set (P9–P10) to obtain the full-length Q8N1X9
transcript (Figure 1a). The 995-bp fragment was detected
in the two homozygous 6493AA and the one hetero-
zygous 6493GA samples (Figure 4) and confirmed by
sequence analysis (data not shown), whereas Q8N1X9
transcript was absent in wild-type 6493GG sample.
Therefore, Q8N1X9 transcript is expressed in human
brainstem tissues carrying the SNP (rs1386493).
SNP (rs1386493) in depression cohorts
Given the functional significance associated with the
A allele of SNP (rs1386493), we hypothesized that it
could be associated with the clinical diagnosis of
depression. We genotyped the A-allele frequency in
Caucasian subjects of the STAR*D (N=1084)
20,21 and
control (N=1200) cohorts, but found no significant
differences (0.17 vs 0.18). In addition, a similar
distribution of the A-allele frequency (0.21) was
found in a set of 99 Caucasian probands derived from
multiplex families of the NIMH Center for Genetic
Studies Depression Pedigree.
22 However, further
analysis of four families whose probands were
homozygous for the A allele revealed 11 of 16 indi-
viduals were homozygous for the A allele (Figure 5).
Discussion
The average vertebrate gene is B27000bp long
separated by multiple small exons each of 150–
300bp.
23 It has been estimated that at least 74% of
human genes are alternatively spliced,
24 and B15%
of all point mutations causing human genetic disease
result from mRNA splicing defects.
25 This suggests
that diverse effects on development, physiology, as
Figure 3 Characterization of genomic elements and
Q8N1X9 transcript. (a) A 1500-bp genomic DNA sequence
downstream of exon a6A, (a6A/U, gray box) was cloned
into a pBluescript vector with a CMV promoter and a
green fluorescent protein (GFP) gene as shown. (b) After
transfection into HEK293 cells, western blotting indicated
that GFP was expressed only in the presence of a6A/U
sequences. (c) A plasmid encoding full-length TPH2 was
co-transfected with or without a plasmid encoding trun-
cated TPH2-TR into PC12 cells. Products were detected by
western blotting for the hemagglutinin (HA) epitope tag
using actin as a control (d) 5-HT production was determined
by HPLC after normalizing full-length TPH2 expression
and using endogenous dopamine as an internal control
as described previously.
8,9 (All data are presented as
means±s.d. Statistical significance of all data presented
was analyzed by Student’s t-test; N=3.) The color reproduc-
tion of this figure is available on the html full text version of
the manuscript.
Figure 4 Q8N1X9 in human brainstem tissues. (a) RT–PCR
of postmortem brainstem tissues followed by nested PCR
analysis. (b) PCR primer sets (P8–P5 and P9–P10) were
designed according to predicted Q8N1X9 transcript. RT–
PCR product from human cortical neuron-derived HCN-2
cell line was used as a negative control.
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aberrant splicing and abnormal protein function.
26,27
In fact, emerging evidence indicates that splicing
defects have an important role in many neurologic
diseases.
28–30 Here, we identify a functional intronic
mutation in the human TPH2 gene that generates an
alternatively spliced form Q8N1X9, consisting of the
first 5 exons of TPH2 gene plus an additional 145bp
of exon a6A (Figures 1a, 2 and 4).
Our identification of a functional role for the SNP
(rs13286493) in alternative splicing is also corrobo-
rated by bioinformatic examination of TPH2 intronic
sequences. Exon recognition requires not only the
traditional 50-, 30-splice sites and branch sites, but also
both exonic and intronic splicing enhancers and
silencers.
28 A growing family of serine/arginine-rich
proteins
31 have been well characterized for their role
as splicing factors through binding to exonic splicing
enhancers. Upstream sequences of exon a6A conform
to a ‘canonical’ intron–exon junction, and the
ESEfinder tool
32 predicts that sequences surrounding
SNP (rs1386493) can serve as recognition sites for two
splicing factors (SF2/ASF and SC35), whereas the A
allele would cause reduced binding of these putative
splicing factors. Interestingly, SF2/ASF has been
previously shown to function as a repressor of
downstream exon recognition when its binding site
is located in an intron.
33 Therefore, the accuracy of
normal intron 5 splicing could, at least in part, be due
to the binding of SF2/ASF, and the A allele could
partially remove the inhibitory element thereby
causing recognition of exon a6A.
TPH2 consists of an N-terminal regulatory domain,
a catalytic domain and a C-terminal tetramerization
domain, and belongs to the superfamily of aromatic
amino-acid hydroxylases including tyrosine hydro-
xylase, phenylalanine hydroxylase and TPH1.
34 As
the truncated TPH2-TR retains the entire regulatory
domain and a small portion of catalytic domain
(Figure 1a), its dominant-negative activity may lie in
its interference with the normal function of the
regulatory domain in the full-length protein.
35,36
A number of genetic analyses have indicated
association between the TPH2 gene and central
nervous system disorders like depression,
14 bipolar
disorder
37,38 and attention-deficit/hyperactivity dis-
order.
39 A functional characterization was carried out
for a rare loss-of-function R441H mutation in an
elderly depression cohort whose patients experienced
life-long depression, and were resistant to treatment.
9
Recently, transgenic knock-in mice carrying the
equivalent human R441H mutation were shown to
recapitulate the predicted >80% decrease in brain 5-
HT synthesis and to exhibit behavioral abnormalities
similar to certain endophenotypes of depression and
anxiety.
40 Similarly, the SNP rs1386493 has been
previously studied as a common genetic variant. Zill
et al.
14 identified an A-allele frequency of 19% in
control subjects (N=265), which was similar to that
in a depression cohort (N=300). In another study,
Haghighi et al.
15 showed an A-allele frequency of 7.2
and 21.3% in depression (N=82) and control (N=80),
respectively (P=0.001), but the authors concluded
that ‘the association with SNP (rs1386493) might be
spurious’ due to a relatively small cohort in the study
and somewhat unexpected finding that the mutated
allele was more frequent in the control cohort.
Haghighi et al.
15 speculated that variants within this
region of the gene might contribute to the generation
of the shorten transcript from the TPH2 gene. Our
functional characterization, however, reveals a poten-
tial mechanism for the pathological function of this
common SNP. It will be of great interest for further
investigation to ascertain the potential epistatic
interaction between this common SNP and genetic
variants in genes related to brain 5-HT homeostasis
including the 5-HT transporter, the vesicular mono-
amine transporter 2 (VMAT2), 5-HT receptors as well
as other TPH2 variants.
The identification of another functional SNP
(rs1386493) in this study in addition to several other
functional variants reported in the TPH2 gene
10–12 are
reminiscent of the characterization of over 400 functional
mutations in phenylalanine hydroxylase (PAH) gene,
which cause various degrees of hyperphenylalaninemia
and its severe symptom, phenylketonuria.
41 Moreover,
a recent study of the TPH2 gene in postmortem brain
tissues has identified a number of rare mutations that
affect splicing or arise from RNA editing.
42 Therefore,
these data strongly suggest that multiple common or
rare functional genetic variants in a single or multiple
susceptibility genes could contribute to 5-HT-related
psychiatric conditions.
13,43–45
Major depression is a complex heterogeneous
disorder with markedly different clinical profiles
Figure 5 Genotyping of samples from four pedigrees
whose probands were homozygous AA in the NIMH Center
for Genetic Studies Depression Pedigree. ‘AA,’ ‘GA,’ ‘GG’
indicate homozygous AA, heterozygous GA and wild-type
GG for single-nucleotide polymorphism (SNP) (rs1386493),
respectively. Arrows show probands where homozygous
SNP (rs1386493) was identified. ‘?’ indicates unknown
genotypes (missing DNA samples).
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1,46–48 and may also
represent a disorder with different endophenotypes
49
or with other comorbid psychiatric conditions.
50–53
Genetic susceptibility, in addition to environmental
and biochemical influences, have been extensively
studied for the etiology of depression.
1 However, the
existence of both genetic and non-genetic risk factors,
as well as limitations in diagnostic criteria,
54 are
major challenges in understanding the molecular
mechanisms underlying the symptoms of depression.
This SNP (rs1386493) is a relatively common variant
(18–20% prevalence) of the THP2 gene that has been
reported in previous studies.
14,15 However, its relation
to depression has been difficult to ascertain. Although
the STAR*D cohort represents unrelated individuals
diagnosed with depression, the 99 probands geno-
typed in this study were selected from multiplex
families in the NIMH Depression Pedigree, which
presumably harbors stronger genetic influences. In
fact, in an examination of four families in which the
probands were homozygous, 11 of 16 individuals
were AA allele carriers (Figure 5). The identification
of the homozygous mutant allele in these families
raises the possibility that this mutation may con-
tribute to familial forms of depression. As the number
of probands from the multiplex families in NIMH
Depression Pedigree is too small to achieve signifi-
cance, further studies with larger cohorts of multiplex
families will be needed to determine the relevance of
this dominant-negative mutant allele to depression or
other psychiatric disorders.
Functional genetic variants are important for our
understanding of the pathophysiology of human dis-
eases. Although coding non-synonymous mutations are
rare, but relatively easy to characterize, coding synon-
ymous, intronic, as well as promoter and untranslated
region variants are more common, but difficult to study.
Minigene constructs using partial genomic DNA are
useful tools to address the functionalities of these
variants by comparing normal gene patterns with those
carrying either one or more genetic variants. This is
especially helpful for studying psychiatric disorders in
which the availability of tissues is limited to post-
mortem brains. Functional characterization of SNP
(rs1386493) and its pathological consequences suggest
that the TPH2 gene deserves further attention as a
potential risk factor for depression.
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